Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
PharmaEssentia Announces Positive Phase 3 Data for Ropeginterferon Alfa-2b
Details : BESREMi (ropeginterferon alfa-2b-njft) targets IFNAR to initiate downstream signaling through the activation of JAK1 and TYK2 and STAT proteins. It is being investigated for essential thrombocythemia.
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaEssentia Completes Enrollment for Phase 2b and Phase 3 Trials in Blood Disorders
Details : BESREMi (ropeginterferon alfa-2b-njft) targets IFNAR to initiate downstream signaling through the activation of JAK1 and TYK2 and STAT proteins. It is being investigated for essential thrombocythemia.
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
June 25, 2024
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is indicated for the polycythemia vera.
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $462.7 million
Deal Type : Public Offering
Details : The net proceeds from the offering will be used to to support growth plans and pipeline development, including Besremi (ropeginterferon alfa-2b-njft), an innovative monopegylated, long-acting interferon for the treatment of polycythemia vera (PV) in adul...
Product Name : Besremi
Product Type : Protein
Upfront Cash : Undisclosed
April 21, 2023
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $462.7 million
Deal Type : Public Offering
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is being investigated for polycythemia vera.
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
March 05, 2023
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Pint Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, i...
Product Name : Besremi
Product Type : Protein
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Pint Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BESREMi (ropeginterferon alfa-2b-njft), is an innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks.
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : P1101 (ropeginterferon alfa-2b-njft) is unique monopegylated, long-acting interferon to treat adults with polycythemia vera. Given well-established safety and efficacy profile demonstrated in prior studies, treatment may represent useful alternative to a...
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable